TGFB1 and neoplasm: A common theme of several recent preclinical therapeutic studies is that high CD4+ T cell levels may be predictive of a favorable response to TGFβ signaling blockade, potentiating TGI and immune-mediated tumor regression in response to ICB (Dodagatta-Marri et al. 2019, Jiao et al. 2019, Li et al. 2020, Liu et al. 2020).